Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Thrivent Financial for Lutherans

Posted by on May 14th, 2023

Thrivent Financial for Lutherans reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 72.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,279 shares of the medical research company’s stock after selling 60,288 shares during the period. Thrivent Financial for Lutherans’ holdings in Charles River Laboratories International were worth $5,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. increased its position in Charles River Laboratories International by 3.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 6,955 shares of the medical research company’s stock valued at $1,515,000 after buying an additional 215 shares in the last quarter. Jensen Investment Management Inc. increased its position in Charles River Laboratories International by 32.9% during the 4th quarter. Jensen Investment Management Inc. now owns 23,080 shares of the medical research company’s stock valued at $5,029,000 after buying an additional 5,710 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Charles River Laboratories International by 35.1% in the fourth quarter. Van ECK Associates Corp now owns 61,199 shares of the medical research company’s stock valued at $13,335,000 after purchasing an additional 15,893 shares during the period. Nordea Investment Management AB increased its holdings in shares of Charles River Laboratories International by 21.6% in the fourth quarter. Nordea Investment Management AB now owns 3,906 shares of the medical research company’s stock valued at $850,000 after purchasing an additional 693 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Charles River Laboratories International by 30.1% in the fourth quarter. Russell Investments Group Ltd. now owns 23,097 shares of the medical research company’s stock valued at $5,044,000 after purchasing an additional 5,344 shares during the period. 97.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CRL shares. Morgan Stanley cut their price objective on Charles River Laboratories International from $241.00 to $230.00 and set an “equal weight” rating on the stock in a report on Thursday, February 23rd. Wells Fargo & Company cut their price objective on Charles River Laboratories International from $290.00 to $280.00 in a report on Friday. Citigroup cut their price objective on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating on the stock in a report on Thursday, February 23rd. Credit Suisse Group cut their price objective on Charles River Laboratories International from $260.00 to $255.00 in a report on Friday. Finally, StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, May 5th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $260.73.

Insiders Place Their Bets

In other news, COO Birgit Girshick sold 3,205 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.39, for a total transaction of $815,319.95. Following the sale, the chief operating officer now owns 41,038 shares in the company, valued at $10,439,656.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Shannon M. Parisotto sold 4,558 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.41, for a total transaction of $1,159,600.78. Following the sale, the executive vice president now owns 6,010 shares in the company, valued at $1,529,004.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick sold 3,205 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.39, for a total value of $815,319.95. Following the sale, the chief operating officer now owns 41,038 shares in the company, valued at approximately $10,439,656.82. The disclosure for this sale can be found here. Insiders sold 27,763 shares of company stock valued at $6,974,921 in the last ninety days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 2.3 %

CRL opened at $191.24 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $181.22 and a 52 week high of $262.00. The business has a fifty day simple moving average of $198.07 and a 200-day simple moving average of $219.35. The firm has a market cap of $9.79 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.34 and a beta of 1.34. The company has a quick ratio of 1.08, a current ratio of 1.32 and a debt-to-equity ratio of 0.91.

Charles River Laboratories International (NYSE:CRL – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 EPS for the quarter, topping the consensus estimate of $2.75 by $0.23. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.04 billion. Charles River Laboratories International had a return on equity of 20.98% and a net margin of 12.23%. The company’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period last year, the business posted $2.49 earnings per share. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current year.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

Featured Articles

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.